Meeting of the CTTI/FDA Patient Engagement Collaborative (PEC) and EMA Patients and Consumers Working Party (PCWP), Online, from 20/07/2023 to 20/07/2023

Human medicines European public assessment report (EPAR): Eporatio, epoetin theta, Kidney Failure, Chronic;Anemia;Cancer, Date of authorisation: 29/10/2009, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Dafiro HCT, amlodipine besilate,valsartan,hydrochlorothiazide, Hypertension, Date of authorisation: 03/11/2009, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Biopoin, epoetin theta, Kidney Failure, Chronic;Anemia;Cancer, Date of authorisation: 23/10/2009, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Copalia HCT, amlodipine,valsartan,hydrochlorothiazide, Hypertension, Date of authorisation: 03/11/2009, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Trepulmix, treprostinil, Hypertension, Pulmonary, Date of authorisation: 03/04/2020, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Sovaldi, sofosbuvir, Hepatitis C, Chronic, Date of authorisation: 16/01/2014, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR): Vosevi, sofosbuvir,velpatasvir,voxilaprevi, Hepatitis C, Chronic, Date of authorisation: 26/07/2017, Revision: 16, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Tofacitinib, decision type: , therapeutic area: , PIP number: P/0055/2017

Human medicines European public assessment report (EPAR): Harvoni, ledispavir,sofosbuvir, Hepatitis C, Chronic, Date of authorisation: 17/11/2014, Revision: 28, Status: Authorised